September 2013 : Treatment: Pot--the Next HIV Drug? - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

Older and Wiser

Mandating Mail-Order Pharmacies

From the Editor

Touch of Gray

Feedback

Letters-September 2013

The POZ Q+A

Committed to the Fight

POZ Planet

Lost Worlds

We the LGBTHIV...

Testing the Limits

Say What-Dan Savage

Check Them Out

Try the Power of Bareback and Body

Burden of Proof

Citizen Scientists

Voices

Light and Darkness

Care and Treatment

GMHC Treatment Issues September 2013

Caring Docs Retain Patients

Breaking the Blood-Brain Barrier

HIV Capsid Structure Defined

Found: Those Lost to Follow-up

Combo of Two HIV Drugs Can Control Hep B

Research Notes

Prevention: Repurposing Vaginal Gel for Rectal Use

Treatment: Pot--the Next HIV Drug?

Cure: Misleading Reports Say Cure Is Near

Concerns: Another Vaccine Trial Shuts Down

POZ Survey Says

Ourselves, Growing Older

POZ Heroes

Musical Missionary

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

September 2013

Treatment: Pot--the Next HIV Drug?

by Benjamin Ryan

Synthetic anti-inflammatory compounds derived from cannabinoids, the primary active ingredient in marijuana, appear to show potential to fight HIV. Cannabinoids activate proteins called CB2 receptors on the surface of immune cells. In the lab, researchers treated HIV-infected macrophage cells with one of three different synthetic cannabinoid compounds that bound to and activated CB2. After a week-long period, all three compounds apparently fought HIV replication. Because HIV requires inflammatory factors inside human cells to replicate efficiently, researchers theorize that activating CB2 appears to fight the virus by decreasing the availability of such factors. The findings suggest that these “CB2 agonists” could be a potential addition to antiretroviral therapy, and that the immune system could be prompted to fight HIV using similar means. People wouldn’t get high off the therapy, though, because the psychoactive element of pot results from interactions with the CB1 receptor.

Search: cannabinoids, marijuana, CB2 receptors

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    acousticmat
    Tucson
    Arizona


    Loveladyd
    Washington
    DC


    sefarady
    New York
    California


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.